€15.50
0.64% today
Xetra, Dec 03, 05:35 pm CET
ISIN
DE0005659700
Symbol
EUZ
Index

Eckert & Ziegler Strahlen- und Medizintechnik Stock price

€15.50
-1.13 6.79% 1M
-5.67 26.77% 6M
+0.67 4.49% YTD
+0.08 0.52% 1Y
-1.15 6.90% 3Y
+2.43 18.63% 5Y
+14.07 980.52% 10Y
+14.68 1,792.78% 20Y
Xetra, Closing price Wed, Dec 03 2025
-0.10 0.64%
ISIN
DE0005659700
Symbol
EUZ
Index

New AI Insights on Eckert & Ziegler Strahlen- und Medizintechnik Insights AI Insights on Eckert & Ziegler Strahlen- und Medizintechnik

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
€996.1m
Enterprise Value
€921.4m
Net debt
positive
Cash
€121.0m
Shares outstanding
62.6m
Valuation (TTM | estimate)
P/E
24.0 | 19.4
P/S
3.3 | 3.1
EV/Sales
3.0 | 2.9
EV/FCF
20.8
P/B
4.3
Dividends
DPS
€0.17
Yield 1Y | 5Y
1.1% | 0.8%
Growth 1Y | 5Y
1,004.0% | 5.4%
Payout 1Y | 3Y
31.5% | 23.6%
Increased
1 Year
Financials (TTM | estimate)
Revenue
€304.5m | €321.3m
EBITDA
€85.6m | €93.9m
EBIT
€64.8m | €77.6m
Net Income
€39.8m | €50.4m
Free Cash Flow
€44.3m
Growth (TTM | estimate)
Revenue
9.6% | 8.6%
EBITDA
14.9% | 33.8%
EBIT
7.5% | 20.0%
Net Income
35.3% | 51.5%
Free Cash Flow
30.5%
Margin (TTM | estimate)
Gross
47.3%
EBITDA
28.1% | 29.2%
EBIT
21.3%
Net
13.1% | 15.7%
Free Cash Flow
14.5%
Financial Health
Equity Ratio
50.5%
Return on Equity
14.9%
ROCE
17.6%
ROIC
16.9%
Debt/Equity
0.2
More
EPS
€0.7
FCF per Share
€0.7
Short interest
-
Employees
1k
Rev per Employee
€270.0k
Show more

Is Eckert & Ziegler Strahlen- und Medizintechnik a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,097 stocks worldwide.

Eckert & Ziegler Strahlen- und Medizintechnik Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Eckert & Ziegler Strahlen- und Medizintechnik forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Eckert & Ziegler Strahlen- und Medizintechnik forecast:

Buy
86%
Hold
14%

Financial data from Eckert & Ziegler Strahlen- und Medizintechnik

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
304 304
10% 10%
100%
- Direct Costs 161 161
11% 11%
53%
144 144
8% 8%
47%
- Selling and Administrative Expenses 75 75
12% 12%
25%
- Research and Development Expense - -
-
-
86 86
15% 15%
28%
- Depreciation and Amortization 21 21
46% 46%
7%
EBIT (Operating Income) EBIT 65 65
7% 7%
21%
Net Profit 40 40
35% 35%
13%

In millions EUR.

Don't miss a Thing! We will send you all news about Eckert & Ziegler Strahlen- und Medizintechnik directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eckert & Ziegler Strahlen- und Medizintechnik Stock News

AD HOC NEWS
about 19 hours ago
Eckert & Ziegler SE / DE0005659700
AD HOC NEWS
about 19 hours ago
Eckert & Ziegler SE / DE0005659700
AD HOC NEWS
17 days ago
Eckert & Ziegler Aktie: Explosives Potenzial!
More Eckert & Ziegler Strahlen- und Medizintechnik News

Company Profile

Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. It operates through the following segments: Radiation Therapy, Isotope Products, and Radiopharma. The Radiation Therapy segment includes the production and distribution of medical products for the treatment of cancer using brachytherapy. The Isotope Products segment manufactures and distributes sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment is specialized in the field of molecular imaging and nuclear medicine, supplying different radiopharmaceuticals, radiochemicals and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. The company was founded by Andreas Eckert in 1997 and is headquartered in Berlin, Germany.

Head office Germany
CEO Harald Hasselmann
Employees 1,085
Founded 1997
Website www.ezag.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today